Glenmede Trust’s BioCardia BCDA Stock Holding History

Glenmede Trust’s Portfolio BCDA Stock Details BCDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9	Closed	–	–	1311
2020 Q3	$0	Hold	9	–	–	﹤0.01%	2463
2020 Q2	$0	Hold	9	–	–	﹤0.01%	2446
2020 Q1	$0	Hold	9	–	–	﹤0.01%	3004
2019 Q4	$0	Hold	9	–	–	﹤0.01%	3011
2019 Q3	$0	Buy	+9	New	+$646	﹤0.01%	3008

Other funds holding BCDA

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust's BCDA Position: Q4 2020 in Review

Glenmede Trust sold out of BioCardia (BCDA) in Q4 2020, closing a stake of 9 shares.

Glenmede Trust first reported a position in BCDA in Q3 2019 and held it in 5 quarters. The position peaked at $0 in Q3 2020. 16 funds tracked by Wall St. Rank hold BCDA as of Q4 2020.

Glenmede Trust reported no remaining BioCardia position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 9 BioCardia shares in Q4 2020.
Glenmede Trust first reported a position in BioCardia in Q3 2019 and held it in 5 quarters.
Glenmede Trust's BioCardia position peaked at $0 in Q3 2020.
16 funds tracked by Wall St. Rank held BioCardia as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.